Publication number: 20070054919
Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.
Type:
Application
Filed:
February 14, 2006
Publication date:
March 8, 2007
Inventors:
Stuart Rosenblum, Seong Kim, Qingbei Zeng, Michael Wong, Gopinadhan Anilkumar, Yueheng Jiang, Wensheng Yu, Joseph Kozlowski, Neng-Yang Shih, Bandarpalle Shankar, Brian McGuinness, Guizhen Dong, Lisa Zawacki, Douglas Hobbs, John Baldwin, Yuefei Shao
Publication number: 20060276448
Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates or esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.
Type:
Application
Filed:
February 14, 2006
Publication date:
December 7, 2006
Inventors:
Qingbei Zeng, De-Yi Yang, Stuart Rosenblum, Michael Wong, Gopinadhan Anilkumar, Seong Kim, Wensheng Yu, Joseph Kozlowski, Neng-Yang Shih, Brian McGuinness, Lisa Guise-Zawacki, Doublas Hobbs